ClinicalTrials.gg
CompletedNCT03510338Updated Jul 10, 2018

Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

A Phase 1 interventional study of Sublingual sildenafil and Oral sildenafil in Erectile Dysfunction, sponsored by N4 Pharma UK Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by N4 Pharma UK Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
47th of 50
12 · median 108
Started
2018
with 1 other
Phase 1
6 of 50
none open now
Registered
47th of 50
by date

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 47th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 1, and was the 47th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The study will assess a new biphasic release sildenafil formulation (N4S001), developed by N4 Pharma. The N4S001 tablet contains a total of 100 mg sildenafil.

The N4S001 tablet is designed to provide a faster onset of release and a longer therapeutic window compared to currently marketed sildenafil products.

This is a single centre, open-label, four-arm crossover study in up to 12 healthy male volunteers.

The following treatments will be dosed:

Assessment Visit 1: N4S001 tablet containing 100 mg sildenafil (fasted)

Assessment Visit 2: N4S001 tablet containing 100 mg sildenafil (fed)

Assessment Visit 3: Viagra film-coated tablet containing 50 mg sildenafil (fasted)

Assessment Visit 4: Viagra film-coated tablet containing 50 mg sildenafil (fed)

The immediate release layer of each N4S001 tablet will be radiolabelled to contain 4 MBq (megabecquerel) 99mTc at time of dose.

Read the detailed description

A pharmacoscintigraphic clinical study will be undertaken to quantify the scintigraphic kinetics and extent of dispersion of the immediate release portion of the N4S001 tablet in the oral cavity, and to measure sildenafil and its main metabolite, N-desmethyl sildenafil, in the blood plasma. The study will comprise an open-label, four-treatment crossover study in up to 12 healthy male volunteers. All subjects will receive four treatments throughout the study. The initial fast onset release portion of each N4S001 tablet will be radiolabelled to enable the dispersion characteristics of this part of the formulation to be investigated in-vivo. The immediate release portion of the N4S001 tablet will be radiolabelled to contain approximately 4 MBq technetium-99m (99mTc) at time of dose (TOD). Blood samples will be taken at pre-defined times to allow pharmacokinetic (PK) evaluation of drug absorption of the N4S001 tablet and of the reference product, Viagra 50 mg film coated tablets. Blood pressure will be recorded at set time intervals to assess the effects of the N4S001 tablet against the reference product. Subjects will also assess the taste acceptability of the N4S001 tablet using a 7-point categorical scale and oral examinations will be completed to assess any local oral effects of N4S001.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Aged between 18 and 65 years inclusive
  • between 18 and 30 kg/m2 inclusive
  • Body weight ≥50 kg
  • Understands and is willing, able and likely to comply with all study procedures and restrictions
  • Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written (signed and dated) obtained before any trial related activities
  • Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or physical examination

Exclusion criteria

Exclusion Criteria:

  • Current or recurrent disease that, in the opinion of the physician responsible, could affect the study conduct or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure).
  • Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures.
  • A history of current or relevant previous non self-limiting gastrointestinal disorders.
  • Currently suffering from disease known to impact gastric emptying, e.g. migraine, Type 1 or Type 2 diabetes mellitus.
  • Currently suffering from any oromucosal condition (e.g. salivary gland disorders, xerostomia, aphthous ulcers) or recent oral surgery that in the opinion of the physician responsible could interfere with the study objectives.
  • Currently or previously suffering from non-arteritic anterior ischaemic optic neuropathy (NAION).
  • Known hereditary degenerative retinal disorders such as retinitis pigmentosa.
  • Hypotension (blood pressure \<90/50 mmHg).
  • Recent history of stroke or myocardial infarction.
  • Laboratory screening results that suggest an abnormal liver and/or renal function.
  • Subject has a screening value of greater than or equal to 450 msec or an that is not suitable for QTc measurements (e.g. poorly defined termination of the T-wave). The ECG taken at screening must be considered not by the Investigator/ study physician.
  • As a result of a physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
  • Subject has taken prescribed medication within 14 days prior to the first assessment visit which, in the opinion of the physician responsible, will interfere with the study procedures or compromise safety. Subjects will be withdrawn from subsequent study days if they commence taking prescribed medication during the study period which, in the opinion of the physician responsible, will interfere with the study procedures or compromise safety.
  • Subject has taken over-the-counter (OTC) medication within 48 hours prior to the first assessment visit. This includes the use of vitamins and natural or herbal remedies. Subjects who have taken OTC medication may still be entered into the study if, in the opinion of the physician responsible, the medication will not interfere with the study procedures or compromise safety.
  • Concomitant use of other phosphodiesterase 5 (PDE5) inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil (REVATIO), or other treatments for erectile dysfunction.
  • Concomitant use of antihypertensive medications (e.g. diuretics, angiotensin converting enzyme (ACE) inhibitors etc).
  • Concomitant use of nitrate medications.
  • Recent history (within the last year) of alcohol or other substance abuse.
  • Subject has an average weekly alcohol intake of greater than 21 units.
  • Subject has positive urine drugs of abuse test at screening.
  • Subject has a positive breath alcohol test at screening.
  • Subject has recently discontinued smoking (less than 3 months).
  • Subject is currently a smoker or user of nicotine-containing products.
  • Subject has a positive urine cotinine test at screening.
  • Subject has a history of allergy to sildenafil, to any component of the dosage form, or any other allergy, which in the opinion of the physician responsible, contraindicates their participation.
  • Has an allergy to any of the contents of the standardised meals.
  • Subject is vegetarian.
  • Subject is lactose intolerant.
  • Participation in another clinical study (inclusive of final post-study examination) or receipt of an drug within the 12 weeks before first screening visit.
  • Previous participation in this study.
  • Subject whose participation in this study will result in participation in more than four studies over a twelve month period.
  • An employee of the sponsor, client or study site or members of their immediate family.
  • Subjects for whom participation in this study will exceed the limits of total radiation exposure allowed in the previous twelve month period (5 mSv), or will exceed 10 mSv over the previous three year period.
  • Subjects who are intending to father a child in the 3 months following the study or are unwilling to abstain from sexual intercourse with pregnant or lactating women.
  • Subjects who are unwilling to use a condom/spermicide in addition to having their female partner use another form of such as an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation if the woman could become pregnant from the time of the assessment visit until 3 months following the study.
  • Subject has donated blood or experienced significant blood loss within 3 months of screening and for the duration of the study.
  • Difficulty accessing forearm veins for cannulation or blood sampling.
  • Subject has any non-removable metal objects such as metal plates, screws etc in their chest or abdominal area, which in the opinion of the investigator, could affect the study conduct.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sublingual sildenafil (fasted)

    Subjects receive a single dose of 100 mg sildenafil

    Drug: Sublingual sildenafil

  • Active comparator
    Oral sildenafil (fed)

    Subjects receive a single dose of 50 mg sildenafil (Viagra)

    Drug: Oral sildenafil

  • Experimental
    Sublingual sildenafil (fed)

    Subjects receive a single dose of 100 mg sildenafil

    Drug: Sublingual sildenafil

  • Active comparator
    Oral comparator (fasted)

    Subjects receive a single dose of 50 mg sildenafil (Viagra)

    Drug: Oral sildenafil

Interventions

06

What researchers measure

Primary outcomes

  1. Sildenafil plasma concentrations

    Measure sildenafil and its main metabolite in plasma and compare pharmacokinetic profiles with that of a marketed sildenafil product in fed and fasted states

    Time frame: 24 hours

Secondary outcomes

  1. Extent of dispersion

    Quantification of extent of dispersion of the immediate release portion of the radiolabelled N4S001 tablet in the oral cavity using gamma scintigraphy

    Time frame: 1 hour

  2. Visualisation of kinetics

    Quantification the kinetics in the oral cavity of the immediate release portion of the radiolabelled N4S001 tablet using gamma scintigraphy

    Time frame: 1 hour

  3. Change in oral examination findings post-dose

    Assess changes in the oral cavity following dosing of the N4S001 tablet

    Time frame: 1 hour

  4. Blood pressure

    Systolic \& diastolic measurements will be used to assess the effects of the N4S001 tablet compared with the marketed sildenafil product

    Time frame: 24 hours

  5. Heart Rate

    Measurements will be used to assess the effects of the N4S001 tablet compared with the marketed sildenafil product

    Time frame: 24 hours

  6. Questionnaire

    Assessment of taste acceptability using a 7-point categorical scale

    Time frame: 1 hour

07

Study locations

1 site
  • BDD Pharma Ltd
    Glasgow, G4 0SF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jun 2018, 1 month.

Of 18 phase 1 interventional studies under Erectile Dysfunction, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 19. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2018
First posted
Apr 27, 2018
StartActual
May 8, 2018
Primary completionActual
Jun 13, 2018
CompletionActual
Jun 13, 2018
Last update
Jul 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03510338
Lead sponsor
N4 Pharma UK Ltd.
Collaborators
BDD Pharma Ltd
Responsible party
Sponsor
First posted
Apr 27, 2018
Start date
May 8, 2018
Primary completion
Jun 13, 2018
Completion
Jun 13, 2018
Last update
Jul 10, 2018

Study contacts

Howard NE Stevens, FRPharmS
principal investigator · BDD Pharma Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion